How Clinically Efficient Is Lumacaftor/Ivacaftor for Cystic Fibrosis Patients? An Updated Literature Review.

Cureus · 2020 · PMC7834585 · PMID 33520477

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

They assessed the safety of LUM/IVA in a long-term fashion with the findings of a decreasing trend of PEx, for a 12-month duration with LUM/IVA.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.